INRLF VALNEVA SE
- 4.500
- +0.460+11.39%
VALNEVA SE News
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for Its Single-Shot Chikungunya Vaccine
Declaration of Shares and Voting Rights April 30, 2024 - VALNEVA SE
Declaration of Voting Rights - Valneva SE, March 2024
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Valneva GAAP EPS of -€0.73, Revenue of €153.71M; Updates FY24 Guidance
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility With Deerfield and OrbiMed
VALNEVA Declaration of Shares and Voting Rights - February 29, 2024
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
Valneva, Pfizer Delay End Date of Lyme Disease Vaccine Phase 3 Trial to 2025
Pfizer, Valneva Removes ~50% Participants in Lyme Disease Vaccine Trial on Violation Woes
Valneva Stock Rises as It Seeks FDA Approval of Single-shot Chikungunya Vaccine
Valneva Reports Q3 Results; Reaffirms FY22 Guidance
Valneva Upsizes Stock Offering to Raise ~€102.9M to Fund Lyme/chikungunya Vaccines
Valneva (NASDAQ:VALN) (OTCPK:INRLF) upsized an offering to raise ~€102.9M (~$99.9M) from the previously expected $40M due to excess demand. The French vaccine maker is pricing of 21M ordinary shares i
Valneva Stock Dips as US DoD Ends Japanese Encephalitis Vaccine Ixiaro Supply Deal
Valneva (NASDAQ:VALN) (OTCPK:INRLF) (OTC:VNVLF) said the U.S. Department of Defense (DoD) decided not to exercise the second option year of the contract to get the company's Japanese encephalitis (JE)
Valneva launches up to $75M at-the-market ADS offering program
Valneva (NASDAQ:VALN) entered in a new financing program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0M of American Deposi
Valneva stock falls as FY22 outlook cut on lower COVID vaccine demand, suspends making COVID shots,
Valneva (NASDAQ:VALN) (OTCPK:INRLF) (OTC:VNVLF) reduced its FY22 revenue outlook citing reduced demand for its COVID vaccine from the EU member states. COVID-19 vaccine sales in H1 were €3.8M. However
Valneva agrees to cut COVID vaccine supplies to EU
The European Commission announced an agreement with Valneva (NASDAQ:VALN) (OTCPK:INRLF) (OTC:VNVLF) on Wednesday that would sharply reduce the French biotech's COVID-19 vaccine deliveries to the regio
Pfizer to buy 8.1% stake in Valneva to support Lyme disease vaccine
Valneva (VALN) (OTCPK:INRLF) rose in the Paris stock exchange on Monday in reaction an agreement under which Pfizer (NYSE:PFE) will purchase 8.1% stake in the French vaccine maker to further support t
Analysis
Price Target
No Data
